Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash from Operations (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Cash from Operations for 16 consecutive years, with 29417000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 1518.99% to 29417000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 109442000.0 through Dec 2025, down 594.56% year-over-year, with the annual reading at 109442000.0 for FY2025, 594.56% down from the prior year.
  • Cash from Operations hit 29417000.0 in Q4 2025 for Vanda Pharmaceuticals, up from 31626000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 31803000.0 in Q1 2023 to a low of 33147000.0 in Q1 2025.
  • Historically, Cash from Operations has averaged 810000.0 across 5 years, with a median of 1114500.0 in 2022.
  • Biggest five-year swings in Cash from Operations: surged 1113.56% in 2021 and later plummeted 1518.99% in 2025.
  • Year by year, Cash from Operations stood at 26607000.0 in 2021, then plummeted by 64.61% to 9416000.0 in 2022, then plummeted by 139.63% to 3732000.0 in 2023, then skyrocketed by 51.31% to 1817000.0 in 2024, then tumbled by 1518.99% to 29417000.0 in 2025.
  • Business Quant data shows Cash from Operations for VNDA at 29417000.0 in Q4 2025, 31626000.0 in Q3 2025, and 15252000.0 in Q2 2025.